TY - JOUR
TI - Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
AU - Miltiades, P.
AU - Lamprianidou, E.
AU - Vassilakopoulos, T.P.
AU - Papageorgiou, S.G.
AU - Galanopoulos, A.G.
AU - Vakalopoulou, S.
AU - Garypidou, V.
AU - Papaioannou, M.
AU - Hadjiharissi, E.
AU - Pappa, V.
AU - Papadaki, H.A.
AU - Spanoudakis, E.
AU - Tsatalas, K.
AU - Kotsianidis, I.
JO - Blood cancer journal
PY - 2014
VL - 4
TODO - 2
SP - null
PB - Nature Publishing Group
SN - null
TODO - 10.1038/bcj.2014.9
TODO - antianemic agent;  azacitidine;  granulocyte colony stimulating factor;  interleukin 2 receptor alpha, aged;  antigen expression;  CD34+ cell;  cell type;  chronic myelomonocytic leukemia;  controlled study;  disease course;  down regulation;  event free survival;  female;  flow cytometry;  follow up;  human;  letter;  major clinical study;  male;  myelodysplastic syndrome;  outcome assessment;  overall survival;  relapse;  survival;  treatment duration;  treatment response
TODO - null
ER -